Hohimer Wealth Management LLC Acquires 482 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Hohimer Wealth Management LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 51,778 shares of the biopharmaceutical company’s stock after purchasing an additional 482 shares during the period. Gilead Sciences makes up 1.1% of Hohimer Wealth Management LLC’s portfolio, making the stock its 24th largest position. Hohimer Wealth Management LLC’s holdings in Gilead Sciences were worth $4,195,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Tompkins Financial Corp lifted its position in shares of Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares during the period. Fortitude Family Office LLC bought a new stake in Gilead Sciences during the 4th quarter valued at approximately $29,000. Private Wealth Management Group LLC purchased a new position in shares of Gilead Sciences during the 4th quarter worth approximately $29,000. Sachetta LLC bought a new position in shares of Gilead Sciences in the 4th quarter worth approximately $30,000. Finally, Rakuten Securities Inc. purchased a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $33,000. 83.67% of the stock is owned by institutional investors.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 26th. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a research report on Wednesday, April 24th. Morgan Stanley dropped their price target on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. Mizuho dropped their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, February 22nd. Finally, Cantor Fitzgerald dropped their price target on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $83.69.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock traded down $1.64 during trading on Thursday, hitting $66.16. 3,100,826 shares of the company’s stock traded hands, compared to its average volume of 7,226,526. Gilead Sciences, Inc. has a 1 year low of $64.33 and a 1 year high of $87.86. The business has a 50-day simple moving average of $68.77 and a 200-day simple moving average of $74.70. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The stock has a market capitalization of $82.43 billion, a P/E ratio of 183.78, a PEG ratio of 1.35 and a beta of 0.22.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. During the same quarter last year, the firm posted $1.37 EPS. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, analysts forecast that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.66%. Gilead Sciences’s payout ratio is 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.